Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19471
Title: PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
Authors: Tutuka, Candani S A;Andrews, Miles C;Mariadason, John M;Ioannidis, Paul;Hudson, Christopher;Cebon, Jonathan S;Behren, Andreas
Affiliation: School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, VIC, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 28-Jun-2017
EDate: 2017-06-28
Citation: Molecular cancer 2017; 16(1): 112
Abstract: BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the promotion of precancerous lesions and secondary neoplasms, mainly (but not exclusively) associated with pre-existing mutations in RAS genes. We previously reported a patient with synchronous BRAF-mutated metastatic melanoma and BRAF wt /KRAS G12D-metastatic colorectal cancer (CRC), whose CRC relapsed and progressed when treated with the BRAF inhibitor dabrafenib (GSK2118436). We used tissue from the resected CRC metastasis to derive a cell line, LM-COL-1, which directly and reliably mimicked the clinical scenario including paradoxical activation of the MAPK signalling pathway resulting in increased cell proliferation upon dabrafenib treatment. Novel BRAF inhibitors (PLX8394 and PLX7904), dubbed as "paradox breakers", were developed to inhibit V600 mutated oncogenic BRAF without causing paradoxical MAPK pathway activation. In this study we used our LM-COL-1 model alongside multiple other CRC cell lines with varying mutational backgrounds to demonstrate and confirm that the paradox breaker PLX8394 retains on-target inhibition of mutated BRAF V600 without paradoxically promoting MAPK signalling.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19471
DOI: 10.1186/s12943-017-0684-x
ORCID: 0000-0001-5329-280X
PubMed URL: 28659148
Type: Letter
Subjects: BRAF
Colorectal cancer
MAPK pathway
Melanoma
Paradoxical activation
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.